| Symbol | RDHL |
|---|---|
| Name | REDHILL BIOPHARMA LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 21 HAARBAA STREET, TEL AVIV, 6473921, Israel |
| Telephone | +972 35413131 |
| Fax | — |
| — | |
| Website | https://www.redhillbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001553846 |
| Description | Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohns disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases. Additional info from NASDAQ: |
New Form F-3 - RedHill Biopharma Ltd. <b>Filed:</b> 2026-07-02 <b>AccNo:</b> 0001178913-26-003394 <b>Size:</b> 536 KB
Read moreNew Form 424B5 - RedHill Biopharma Ltd. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001178913-26-003349 <b>Size:</b> 616 KB
Read moreRedHill Biopharma - RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
Read moreRedHill Biopharma - RedHill Biopharma Announces Up To $19.4 Million Private Placement
Read moreRedHill Biopharma - RedHills Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
Read moreRedHill Biopharma - RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
Read moreRedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
Read moreRedHill Biopharma - RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
Read moreNew Form 424B5 - RedHill Biopharma Ltd. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001178913-26-002450 <b>Size:</b> 20 KB
Read moreNew Form EFFECT - RedHill Biopharma Ltd. <b>Filed:</b> 2026-05-05 <b>AccNo:</b> 9999999995-26-001495 <b>Size:</b> 1 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03414489 | Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640… | — | Cholangiocarcinoma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT04026984 | Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's… | Phase2 | Traveler's Diarrhea | Unknown | 2024-06-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT05954286 | PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19 | Phase2 | SARS-CoV-2 | Completed | 2024-01-29 | 2025-04-24 | ClinicalTrials.gov |
| NCT04027894 | Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler'… | Phase2 | Traveler's Diarrhea | Unknown | 2024-01-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT04723537 | Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Di… | Phase2 | Covid19 | Terminated | 2021-02-16 | 2021-12-28 | ClinicalTrials.gov |
| NCT04616924 | RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease | Phase3 | Pulmonary Mycobacterium Avium Complex Infection | Terminated | 2020-12-01 | 2023-08-28 | ClinicalTrials.gov |
| NCT04467840 | Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia | Phase2 | COVID-19 | Completed | 2020-08-21 | 2021-07-18 | ClinicalTrials.gov |
| NCT04502069 | Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen | Phase1 | COVID-19 | Withdrawn | 2020-08-01 | 2021-06-01 | ClinicalTrials.gov |
| NCT04414618 | A Study of Opaganib in Coronavirus Disease 2019 Pneumonia | Phase2 | Coronavirus Infections | Completed | 2020-07-02 | 2020-12-23 | ClinicalTrials.gov |
| NCT03377179 | A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment… | Phase2 | Cholangiocarcinoma | Completed | 2018-03-07 | 2022-06-21 | ClinicalTrials.gov |
| NCT03198507 | ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Co… | Phase3 | Helicobacter Pylori Infection | Completed | 2017-06-18 | 2018-12-13 | ClinicalTrials.gov |
| NCT03009396 | Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberc… | Phase3 | Crohn Disease | Completed | 2017-03-18 | 2019-08-19 | ClinicalTrials.gov |
| NCT02757105 | Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondanset… | Phase2 | Irritable Bowel Syndrome With Diarrhea | Completed | 2016-05-19 | 2017-07-14 | ClinicalTrials.gov |
| NCT02246439 | BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presume… | Phase3 | Gastroenteritis | Completed | 2014-12-08 | 2017-02-16 | ClinicalTrials.gov |
| NCT01980095 | ERADICATE Hp - Treating Helicobacter Pylori With RHB-105 | Phase3 | Dyspepsia | Completed | 2013-11-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01951326 | Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2013-09-01 | 2019-08-01 | ClinicalTrials.gov |
| NCT01717664 | Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Re… | Phase2 | Relapsing Remitting Multiple Sclerosis | Completed | 2013-06-01 | 2016-07-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Coronavirus Infections | COMPLETED | NCT04414618 |
| Opaganib | Other | Phase PHASE2 | Coronavirus Infections | COMPLETED | NCT04414618 |
| Hydroxychloroquine Sulfate 200 MG | Other | Phase PHASE2 | Cholangiocarcinoma | COMPLETED | NCT03377179 |
| ABC294640 | Other | Phase PHASE2 | Cholangiocarcinoma | COMPLETED | NCT03377179 |
| RHB-104 | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01717664 |
| Placebo | Other | Phase PHASE2 | Irritable Bowel Syndrome With Diarrhea | COMPLETED | NCT02757105 |
| BEKINDA | Other | Phase PHASE2 | Irritable Bowel Syndrome With Diarrhea | COMPLETED | NCT02757105 |
| Placebo Oral Tablet | Other | Phase PHASE3 | Gastroenteritis | COMPLETED | NCT02246439 |
| RHB-102 | Other | Phase PHASE3 | Gastroenteritis | COMPLETED | NCT02246439 |
| Placebo | Other | Phase PHASE3 | Dyspepsia | COMPLETED | NCT01980095 |
| RHB-105 | Other | Phase PHASE3 | Dyspepsia | COMPLETED | NCT01980095 |
| Active Comparator | Other | Phase PHASE3 | Helicobacter Pylori Infection | COMPLETED | NCT03198507 |
| RHB-105 | Other | Phase PHASE3 | Helicobacter Pylori Infection | COMPLETED | NCT03198507 |
| Opaganib | Other | Phase PHASE1 | COVID-19 | WITHDRAWN | NCT04502069 |
| Placebo | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT01951326 |
| RHB-104 | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT01951326 |
| RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine) | Other | Phase PHASE3 | Crohn Disease | COMPLETED | NCT03009396 |
| Placebo to Rifamycin SV-MMX | Other | Phase PHASE2 | Traveler's Diarrhea | UNKNOWN | NCT04027894 |
| Rifamycin SV MMX | Other | Phase PHASE2 | Traveler's Diarrhea | UNKNOWN | NCT04027894 |
| Placebo | Other | Phase PHASE2 | Traveler's Diarrhea | UNKNOWN | NCT04026984 |
| Rifamycin SV-MMX | Other | Phase PHASE2 | Traveler's Diarrhea | UNKNOWN | NCT04026984 |
| Part B: Upamostat 200 or 400 mg | Other | Phase PHASE2 | Covid19 | TERMINATED | NCT04723537 |
| Part A and B: Placebo | Other | Phase PHASE2 | Covid19 | TERMINATED | NCT04723537 |
| Part A: Upamostat 400 mg | Other | Phase PHASE2 | Covid19 | TERMINATED | NCT04723537 |
| Part A: Upamostat 200 mg | Other | Phase PHASE2 | Covid19 | TERMINATED | NCT04723537 |
| Placebo | Other | Phase PHASE3 | Pulmonary Mycobacterium Avium Complex Infection | TERMINATED | NCT04616924 |
| RHB-204 | Other | Phase PHASE3 | Pulmonary Mycobacterium Avium Complex Infection | TERMINATED | NCT04616924 |
| ABC294640 | Other | Preclinical | Cholangiocarcinoma | NO_LONGER_AVAILABLE | NCT03414489 |
| Placebo | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04467840 |
| Opaganib | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04467840 |
| Placebo (PO) | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05954286 |
| Upamostat | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05954286 |
| Placebo (PO) | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05954286 |
| Upamostat | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05954286 |